FR22C1023I2 - Forme polymorphe st-246 et procedes de preparation - Google Patents

Forme polymorphe st-246 et procedes de preparation

Info

Publication number
FR22C1023I2
FR22C1023I2 FR22C1023C FR22C1023C FR22C1023I2 FR 22C1023 I2 FR22C1023 I2 FR 22C1023I2 FR 22C1023 C FR22C1023 C FR 22C1023C FR 22C1023 C FR22C1023 C FR 22C1023C FR 22C1023 I2 FR22C1023 I2 FR 22C1023I2
Authority
FR
France
Prior art keywords
polymorph form
preparation processes
processes
preparation
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1023C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of FR22C1023I1 publication Critical patent/FR22C1023I1/fr
Application granted granted Critical
Publication of FR22C1023I2 publication Critical patent/FR22C1023I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/724,7-Endo-alkylene-iso-indoles
    • C07D209/764,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
FR22C1023C 2010-03-23 2022-06-02 Forme polymorphe st-246 et procedes de preparation Active FR22C1023I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31674710P 2010-03-23 2010-03-23
US37303110P 2010-08-12 2010-08-12
PCT/US2011/029576 WO2011119698A1 (en) 2010-03-23 2011-03-23 Polymorphic forms st-246 and methods of preparation

Publications (2)

Publication Number Publication Date
FR22C1023I1 FR22C1023I1 (fr) 2022-07-22
FR22C1023I2 true FR22C1023I2 (fr) 2024-02-16

Family

ID=44656766

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1023C Active FR22C1023I2 (fr) 2010-03-23 2022-06-02 Forme polymorphe st-246 et procedes de preparation

Country Status (20)

Country Link
US (6) US9339466B2 (ko)
EP (1) EP2549871B1 (ko)
JP (3) JP6018041B2 (ko)
KR (6) KR20160062208A (ko)
CN (4) CN105111130A (ko)
AP (1) AP3221A (ko)
AU (1) AU2011232551B2 (ko)
BR (1) BR112012023743B1 (ko)
CA (2) CA3030671A1 (ko)
CL (1) CL2012002621A1 (ko)
DK (1) DK2549871T3 (ko)
FR (1) FR22C1023I2 (ko)
IL (4) IL221991B (ko)
MX (1) MX361428B (ko)
NZ (1) NZ602578A (ko)
PE (2) PE20170944A1 (ko)
RU (2) RU2015146899A (ko)
SG (2) SG10201501936PA (ko)
WO (1) WO2011119698A1 (ko)
ZA (1) ZA201207141B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CA3030671A1 (en) * 2010-03-23 2011-09-29 Shanthakumar R. Tyavanagimatt Polymorphic forms of st-246 and methods of preparation
EP2887938B1 (en) * 2012-08-16 2018-01-10 Siga Technologies, Inc. Methods of preparing tecovirimat
AU2014290333B2 (en) * 2013-07-19 2018-11-08 Siga Technologies, Inc. Amorphous Tecovirimat preparation
AU2014353235B2 (en) * 2013-11-19 2019-05-09 Siga Technologies, Inc. Rehydration of micronized tecovirimat monohydrate
AU2015320358B2 (en) * 2014-09-26 2020-05-14 Millendo Therapeutics, Inc. Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto
US11433051B2 (en) 2016-02-16 2022-09-06 Siga Technologies, Inc. ST-246 (tecovirimat monohydrate) suspension formulations
KR20190127687A (ko) 2017-03-31 2019-11-13 오사까 가스 가부시키가이샤 전기 화학 소자, 전기 화학 모듈, 고체 산화물형 연료 전지, 및 제조 방법
RU2716709C1 (ru) * 2019-08-20 2020-03-16 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Пероральная лекарственная форма препарата в капсулах для лечения и профилактики заболеваний, вызываемых ортопоксвирусами
TW202320776A (zh) * 2021-11-04 2023-06-01 日商興和股份有限公司 膠囊劑
WO2023080189A1 (ja) * 2021-11-04 2023-05-11 興和株式会社 医薬品

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670901A1 (de) 1967-08-09 1971-03-18 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US4173646A (en) 1974-10-04 1979-11-06 Merck & Co., Inc. Tricyclicdicarboximides
US4061763A (en) 1975-05-09 1977-12-06 Merck & Co., Inc. Tricyclicdicarboximides
US5068356A (en) 1990-02-20 1991-11-26 Atochem North America, Inc. Hindered phenolic n-(amido)imides
ZA939565B (en) 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
JP4334869B2 (ja) 2000-12-01 2009-09-30 協和発酵キリン株式会社 溶解性または経口吸収性の改善された組成物
US6433016B1 (en) 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7737168B2 (en) 2003-06-20 2010-06-15 Siga Technologies, Inc. Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2004112718A2 (en) 2003-06-20 2004-12-29 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7687641B2 (en) * 2003-06-20 2010-03-30 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US20070122471A1 (en) 2003-12-25 2007-05-31 Takeda Pharmaceutical Company Limited Method of improving suitability for granulation
JP2008523025A (ja) * 2004-12-09 2008-07-03 ザック システム エス.ピー.エー. カルベジロール及びそのエナンチオマーの調製プロセス
EP1868628B1 (en) * 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
WO2007103111A2 (en) 2006-03-02 2007-09-13 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
CA2866037C (en) 2007-04-23 2017-05-16 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN101445478B (zh) * 2008-08-22 2011-04-06 中国人民解放军军事医学科学院生物工程研究所 含一个结晶水的化合物st-246及其晶体与制备方法
RU2412160C1 (ru) * 2009-09-25 2011-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) 7-[n'-(4-трифторметилбензоил)-гидразинокарбонил]-трицикло[3.2.2.02,4]нон-8-ен-6-карбоновая кислота, обладающая противовирусной активностью
CA3030671A1 (en) * 2010-03-23 2011-09-29 Shanthakumar R. Tyavanagimatt Polymorphic forms of st-246 and methods of preparation

Also Published As

Publication number Publication date
PE20130212A1 (es) 2013-03-09
IL221991B (en) 2019-06-30
WO2011119698A1 (en) 2011-09-29
KR20150092354A (ko) 2015-08-12
JP2018012735A (ja) 2018-01-25
CN105111130A (zh) 2015-12-02
CA2793533C (en) 2019-02-26
BR112012023743A2 (pt) 2015-09-15
US20210137885A1 (en) 2021-05-13
AP2012006514A0 (en) 2012-10-31
MX2012010859A (es) 2013-04-29
CN105111131A (zh) 2015-12-02
NZ602578A (en) 2014-08-29
AU2011232551A1 (en) 2012-10-18
US10406137B2 (en) 2019-09-10
SG10201501936PA (en) 2015-05-28
ZA201207141B (en) 2016-06-29
SG184201A1 (en) 2012-10-30
KR20170102070A (ko) 2017-09-06
KR20130018271A (ko) 2013-02-20
KR20150011016A (ko) 2015-01-29
US20110236434A1 (en) 2011-09-29
CA3030671A1 (en) 2011-09-29
EP2549871A4 (en) 2016-03-09
US20180311213A1 (en) 2018-11-01
KR20160062208A (ko) 2016-06-01
AP3221A (en) 2015-04-30
RU2012144818A (ru) 2014-04-27
US20190343799A1 (en) 2019-11-14
US10933050B2 (en) 2021-03-02
US20160107993A1 (en) 2016-04-21
RU2578606C2 (ru) 2016-03-27
AU2011232551B2 (en) 2014-11-13
IL241731A0 (en) 2015-11-30
EP2549871B1 (en) 2018-08-22
CA2793533A1 (en) 2011-09-29
JP2016040323A (ja) 2016-03-24
WO2011119698A9 (en) 2013-01-31
MX361428B (es) 2018-12-06
PE20170944A1 (es) 2017-07-13
JP6018041B2 (ja) 2016-11-02
US11890270B2 (en) 2024-02-06
CN103068232A (zh) 2013-04-24
US10045964B2 (en) 2018-08-14
CL2012002621A1 (es) 2013-10-11
DK2549871T3 (en) 2018-12-10
CN105175311A (zh) 2015-12-23
US9339466B2 (en) 2016-05-17
IL241730A0 (en) 2015-11-30
EP2549871A1 (en) 2013-01-30
CN103068232B (zh) 2015-08-26
BR112012023743B1 (pt) 2020-02-18
IL258239A (en) 2018-05-31
KR20160028489A (ko) 2016-03-11
US20180193308A1 (en) 2018-07-12
US9744154B2 (en) 2017-08-29
RU2015146899A (ru) 2019-01-11
JP2013522371A (ja) 2013-06-13
FR22C1023I1 (fr) 2022-07-22

Similar Documents

Publication Publication Date Title
FR22C1023I2 (fr) Forme polymorphe st-246 et procedes de preparation
BR112013013263A2 (pt) conjunto de conexão
BR112013010000A2 (pt) aparelho de cateter
BR112013011157A2 (pt) aparelho de respiração
DK3246018T3 (da) Farmaceutisk sammensætning
EE201300005A (et) Ravimkoostis
FR3017891B1 (fr) Structures et procedes de coffrage de dalles
BR112013011848A2 (pt) método de conexão melhorado
BR112012022294A2 (pt) articulador
BR112013012506A2 (pt) aparelho de eletrólise
ME02102B (me) Novi polimorf
BR112012021749A2 (pt) processos e compostos
DK2642980T3 (da) Pædiatrisk formulering
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
AT508580A3 (de) Bodenbearbeitungsgerät
DK2279652T3 (da) Kultivator
DK2425046T3 (da) Tæppe
BRPI1014684A2 (pt) novos derivados de isoquinolina
BR112013015580A2 (pt) método de radioestabilização
BR112013000339A2 (pt) dispositivo de fotocura
BR112013007492A2 (pt) glicodendrímeros de polipropileterimina
BR112012010525A2 (pt) novos processos
BR112012029887A2 (pt) composição farmacêutica
EP2539157A4 (en) REMOVABLE TOP BLANKET
FI20105327A0 (fi) Farmaseuttinen koostumus